-
Je něco špatně v tomto záznamu ?
TFEB Expression Profiling in Renal Cell Carcinomas: Clinicopathologic Correlations
S. Gupta, P. Argani, AA. Jungbluth, YB. Chen, SK. Tickoo, SW. Fine, A. Gopalan, HA. Al-Ahmadie, SJ. Sirintrapun, A. Sanchez, AA. Hakimi, T. Mcfarlane, PA. Salazar, SR. Williamson, SL. Skala, R. Mehra, O. Hes, CR. Antonescu, M. Ladanyi, ME....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
Grantová podpora
P30 CA008748
NCI NIH HHS - United States
T32 CA082088
NCI NIH HHS - United States
- MeSH
- dítě MeSH
- dospělí MeSH
- hybridizace in situ fluorescenční MeSH
- imunohistochemie MeSH
- karcinom z renálních buněk diagnóza metabolismus patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádorové biomarkery metabolismus MeSH
- nádory ledvin diagnóza metabolismus patologie MeSH
- následné studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- stanovení celkové genové exprese MeSH
- transkripční faktory BHLH-Zip metabolismus MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
TFEB is overexpressed in TFEB-rearranged renal cell carcinomas as well as in renal tumors with amplifications of TFEB at 6p21.1. As recent literature suggests that renal tumors with 6p21.1 amplification behave more aggressively than those with rearrangements of TFEB, we compared relative TFEB gene expression in these tumors. This study included 37 TFEB-altered tumors: 15 6p21.1-amplified and 22 TFEB-rearranged (including 5 cases from The Cancer Genome Atlas data set). TFEB status was verified using a combination of fluorescent in situ hybridization (n=27) or comprehensive molecular profiling (n=13) and digital droplet polymerase chain reaction was used to quantify TFEB mRNA expression in 6p21.1-amplified (n=9) and TFEB-rearranged renal tumors (n=19). These results were correlated with TFEB immunohistochemistry. TFEB-altered tumors had higher TFEB expression when normalized to B2M (mean: 168.9%, n=28), compared with non-TFEB-altered controls (mean: 7%, n=18, P=0.005). Interestingly, TFEB expression in tumors with rearrangements (mean: 224.7%, n=19) was higher compared with 6p21.1-amplified tumors (mean: 51.2%, n=9; P=0.06). Of note, classic biphasic morphology was only seen in TFEB-rearranged tumors and when present correlated with 6.8-fold higher TFEB expression (P=0.00004). Our results suggest that 6p21.1 amplified renal tumors show increased TFEB gene expression but not as much as t(6;11) renal tumors. These findings correlate with the less consistent/diffuse expression of downstream markers of TFEB activation (cathepsin K, melan A, HMB45) seen in the amplified neoplasms. This suggests that the aggressive biological behavior of 6p21.1 amplified renal tumors might be secondary to other genes at the 6p21.1 locus that are co-amplified, such as VEGFA and CCND3, or other genetic alterations.
Department of Pathology and Laboratory Medicine Henry Ford Health System Detroit
Department of Pathology The Johns Hopkins Medical Institutions Baltimore MD
Department of Pathology University Hospital Plzeň Charles University Pilsen Czech Republic
Department of Pathology University of Michigan Health System Ann Arbor MI
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023505
- 003
- CZ-PrNML
- 005
- 20201214130223.0
- 007
- ta
- 008
- 201125s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/PAS.0000000000001307 $2 doi
- 035 __
- $a (PubMed)31600176
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Gupta, Sounak $u Departments of Pathology.
- 245 10
- $a TFEB Expression Profiling in Renal Cell Carcinomas: Clinicopathologic Correlations / $c S. Gupta, P. Argani, AA. Jungbluth, YB. Chen, SK. Tickoo, SW. Fine, A. Gopalan, HA. Al-Ahmadie, SJ. Sirintrapun, A. Sanchez, AA. Hakimi, T. Mcfarlane, PA. Salazar, SR. Williamson, SL. Skala, R. Mehra, O. Hes, CR. Antonescu, M. Ladanyi, ME. Arcila, VE. Reuter,
- 520 9_
- $a TFEB is overexpressed in TFEB-rearranged renal cell carcinomas as well as in renal tumors with amplifications of TFEB at 6p21.1. As recent literature suggests that renal tumors with 6p21.1 amplification behave more aggressively than those with rearrangements of TFEB, we compared relative TFEB gene expression in these tumors. This study included 37 TFEB-altered tumors: 15 6p21.1-amplified and 22 TFEB-rearranged (including 5 cases from The Cancer Genome Atlas data set). TFEB status was verified using a combination of fluorescent in situ hybridization (n=27) or comprehensive molecular profiling (n=13) and digital droplet polymerase chain reaction was used to quantify TFEB mRNA expression in 6p21.1-amplified (n=9) and TFEB-rearranged renal tumors (n=19). These results were correlated with TFEB immunohistochemistry. TFEB-altered tumors had higher TFEB expression when normalized to B2M (mean: 168.9%, n=28), compared with non-TFEB-altered controls (mean: 7%, n=18, P=0.005). Interestingly, TFEB expression in tumors with rearrangements (mean: 224.7%, n=19) was higher compared with 6p21.1-amplified tumors (mean: 51.2%, n=9; P=0.06). Of note, classic biphasic morphology was only seen in TFEB-rearranged tumors and when present correlated with 6.8-fold higher TFEB expression (P=0.00004). Our results suggest that 6p21.1 amplified renal tumors show increased TFEB gene expression but not as much as t(6;11) renal tumors. These findings correlate with the less consistent/diffuse expression of downstream markers of TFEB activation (cathepsin K, melan A, HMB45) seen in the amplified neoplasms. This suggests that the aggressive biological behavior of 6p21.1 amplified renal tumors might be secondary to other genes at the 6p21.1 locus that are co-amplified, such as VEGFA and CCND3, or other genetic alterations.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a transkripční faktory BHLH-Zip $x metabolismus $7 D051778
- 650 _2
- $a nádorové biomarkery $x metabolismus $7 D014408
- 650 _2
- $a karcinom z renálních buněk $x diagnóza $x metabolismus $x patologie $7 D002292
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a stanovení celkové genové exprese $7 D020869
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunohistochemie $7 D007150
- 650 _2
- $a hybridizace in situ fluorescenční $7 D017404
- 650 _2
- $a nádory ledvin $x diagnóza $x metabolismus $x patologie $7 D007680
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Argani, Pedram $u Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD.
- 700 1_
- $a Jungbluth, Achim A $u Departments of Pathology.
- 700 1_
- $a Chen, Ying-Bei $u Departments of Pathology.
- 700 1_
- $a Tickoo, Satish K $u Departments of Pathology.
- 700 1_
- $a Fine, Samson W $u Departments of Pathology.
- 700 1_
- $a Gopalan, Anuradha $u Departments of Pathology.
- 700 1_
- $a Al-Ahmadie, Hikmat A $u Departments of Pathology.
- 700 1_
- $a Sirintrapun, Sahussapont J $u Departments of Pathology.
- 700 1_
- $a Sanchez, Alejandro $u Surgery, Urology Service. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
- 700 1_
- $a Hakimi, Abraham Ari $u Surgery, Urology Service. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
- 700 1_
- $a Mcfarlane, Tiffany $u Departments of Pathology.
- 700 1_
- $a Salazar, Paulo A $u Departments of Pathology.
- 700 1_
- $a Williamson, Sean R $u Department of Pathology & Laboratory Medicine, Henry Ford Health System, Detroit.
- 700 1_
- $a Skala, Stephanie L $u Department of Pathology, University of Michigan Health System, Ann Arbor, MI.
- 700 1_
- $a Mehra, Rohit $u Department of Pathology, University of Michigan Health System, Ann Arbor, MI.
- 700 1_
- $a Hes, Ondrej $u Department of Pathology, University Hospital Plzeň, Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Antonescu, Cristina R $u Departments of Pathology.
- 700 1_
- $a Ladanyi, Marc $u Departments of Pathology.
- 700 1_
- $a Arcila, Maria E $u Departments of Pathology.
- 700 1_
- $a Reuter, Victor E $u Departments of Pathology.
- 773 0_
- $w MED00000304 $t The American journal of surgical pathology $x 1532-0979 $g Roč. 43, č. 11 (2019), s. 1445-1461
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31600176 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214130222 $b ABA008
- 999 __
- $a ok $b bmc $g 1595824 $s 1114181
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 43 $c 11 $d 1445-1461 $e - $i 1532-0979 $m The American journal of surgical pathology $n Am J Surg Pathol $x MED00000304
- GRA __
- $a P30 CA008748 $p NCI NIH HHS $2 United States
- GRA __
- $a T32 CA082088 $p NCI NIH HHS $2 United States
- LZP __
- $a Pubmed-20201125
